by Silvie Wertwijn | 11 October 2021 | Pharma & Life Sciences
In 2017 and 2018, various fines were imposed by the Minister of Medical Care on the operator of this website (“Dokteronline”), located in Curaçao, for (1) offering without a license so-called UR and UA medicines and advertising such medicines, as well as (2) selling medicines online to Dutch consumers, while it does not have the mandatory EU logo for the online sale of medicines.
read more
by Silvie Wertwijn & Linda Eijpe | 25 September 2020 | Pharma & Life Sciences
Although E-health is a major spearhead in healthcare, there are also forms of digital care that are under scrutiny and have meanwhile been found impermissible by the court.
read more
by Silvie Wertwijn | 25 April 2019 | Pharma & Life Sciences
In our newsletter of April 2017, the Bill for review of the Dutch Medicines Act (DMA) by reason of technical improvements and increase of the fine maximum was already discussed. The final Act was published on 15 November 2018 and entered into force on 1 January 2019.
read more
by Silvie Wertwijn | 25 April 2019 | Intellectual Property, Pharma & Life Sciences
On 1 February 2019, the so-called pharmacist exemption in the Dutch Patent Act 1995 (DPA) has become effective.
read more
by Tessa de Mönnink | 28 December 2018 | Employment law, Employee Participation, Pension law, Franchise, Commercial contracts, Distribution & Agency, Intellectual Property, Privacy, IT & Internet, Pharma & Life Sciences, Mediation
News Announcement Parker Advocaten 28 december 2018 There’s so much we share. So why not share the same name? From 1 January 2019, De Grave De Mönnink Spliet Advocaten is joined by Scope Advocaten, continuing under the name Parker Advocaten. Taking a different... read more
by Silvie Wertwijn | 13 April 2017 | Pharma & Life Sciences
On 16 March 2017, the draft bill amending the Dutch Medicines Act (Geneesmiddelenwet) due to technical improvements and the raising of the maximum penalty was submitted to the Lower House of the Dutch Parliament (Tweede Kamer).
read more